DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.

William Blair reaffirmed their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report ...

In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech ...

In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report), with a price ...

Denali Therapeutics showcases its BBB platform at J.P. Morgan Conference, highlighting DNL310's Hunter syndrome progress and plans for commercialization.

In any case, new support levels are usually revised to the database at the beginning of the next trading session. Short DNLI slightly under 22.09, target n/a, stop loss @ 22.15 Details The technical ...

In a report released today, Brendan Smith from TD Cowen maintained a Buy rating on Denali Therapeutics (DNLI – Research Report). The company’s ...

Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's ...

President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...

DNLI opened at $21.25 on Tuesday. The stock has a fifty day moving average of $24.23 and a 200-day moving average of $24.86. Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...